Document:

EX-10.2

 Exhibit 10.2 
  

			
	

	 	 CymaBay Therapeutics
 7575 Gateway Blvd.

Suite 110
 Newark, CA 94560

www.cymabay.com
 510-293-8800 office
 510-293-9090
fax

 April 30, 2021 
 Dennis D.
Kim, MD 
 Dear Dennis: 
 CymaBay Therapeutics, Inc. (the
“Company”) is pleased to offer you employment as Chief Medical Officer on the following terms, effective as of the date upon which you commence employment with the Company: 

1. Position, Duties and Responsibilities. Subject to the terms set forth herein, the Company agrees to employ you in the
position of Chief Medical Officer. You will report to the Company’s Chief Executive Officer (“CEO”) and will perform such duties as are assigned to you by the CEO. You will devote your full business time and attention to the
business affairs of the Company, except for reasonable vacations and periods of illness or incapacity permitted by the Company’s general employment policies. 

You will be working remotely from Southern California; however, given the executive nature of this key role and its strategic and operational importance to
the Company, once we begin going back into the office in Newark, CA., you agree to travel and work in the office at least two weeks per month for a majority (i.e., 4-5 days) of those weeks. In addition, if
there are other critical meetings or pressing business needs, you agree to travel to the office, as necessary. Finally, during the first six months of work post Labor Day 2021, you agree to be physically onsite commensurate with the rest of the
Senior Management Team, should it require more than the minimal two weeks per month described previously in this paragraph. The CEO and you shall consult with each other from time to time regarding the optimal scheduling of time at the office
depending on the ongoing needs of the business. 
 The employment relationship between you and the Company shall also be governed by the general employment
policies and practices of the Company, including those relating to protection of confidential information and assignment of inventions, except that when the terms of this letter agreement differ from, or are in conflict with, the Company’s
general employment policies or practices, this letter agreement shall control. Subject to the other terms of this letter agreement, the Company may change your position, duties, reporting relationship and work location from time to time in its
discretion. 
 2. Background Check. Employment at the Company is conditioned upon passing a background check. Waivers
necessary to authorize this process will be sent to you by email from Advanced Reporting. Please sign and return the waiver forms electronically according to the instructions you will receive from them. 

  Page
 2
 
  

 3. Compensation and Employee Benefits. 

3.1 Base Salary. Your base salary will be four hundred thirty-six thousand dollars
($436,000) on an annualized basis, less payroll deductions and required withholdings, paid according to the Company’s regular payroll schedule and procedures. Subject to the other terms of this letter agreement, your base salary may be modified
by the Company in its sole discretion. 
 3.2 Sign-On/Retention Bonus. To help induce
you to accept employment with the Company, the Company will pay you twenty-five thousand dollars ($25,000) as a sign-on/retention bonus (the “Sign-On Bonus”).
This Sign-On Bonus will be subject to required payroll deductions and withholdings and will be paid to you within thirty (30) days after you commence employment. This
Sign-On Bonus is not earned until you complete one year of employment with the Company. Therefore, if you resign your employment for any reason prior to the first anniversary of your employment commencement
date, you agree to repay to the Company the full gross amount of the Sign-On Bonus within thirty (30) days after your employment termination, and the Company agrees to make corresponding adjustments to
whatever W-2 and other tax forms as may be implicated. 
 3.3 Discretionary
Bonus. You will be eligible to participate in the Company’s annual bonus program pursuant to the terms of that program and you will be eligible to receive a bonus of up to forty percent (40%) of your annual base salary. Your actual
bonus, if any, will be determined by the Company’s Board of Directors (the “Board”), or the Compensation subcommittee thereof, in its sole discretion, based upon its evaluation of your performance, the Company’s performance, and
any other considerations it deems relevant. For your initial year of employment, your bonus will be pro-rated for the time elapsed in the bonus period for which you were employed by the Company. You must be
employed through the bonus payment date to be eligible for, and to earn, any such bonus. Bonuses are typically paid within sixty (60) days after the end of the calendar year. Any bonus payment will be subject to payroll deductions and required
withholdings. 
 3.4 Employee Benefits. You will be entitled to all employee benefits, including vacation accrual of twenty
(20) days per year and health and disability benefits for which you are eligible under the terms and conditions of the standard Company benefit plans that may be in effect from time to time and provided by the Company to its senior
executive-level employees generally. Currently, such benefits include twelve (12) paid holiday days, as well as paid sick leave of up to five (5) days per year. Notwithstanding the foregoing, the Company reserves the right to adopt, amend
or discontinue any employee benefit plan or policy, including changes required by applicable law. 
 3.5 Stock Options.
Subject to the approval of the Board, or the Board’s Compensation Committee, pursuant to the Company’s equity incentive plan you will be granted a stock option covering four hundred thousand (400,000) shares of Company common stock at a
per share exercise price equal to the per share fair market value of the Company’s common stock on the grant date. The term of such stock option will be ten (10) years, subject to earlier expiration in the event of the termination of your
service with the Company. Such stock option will vest and be exercisable as to twenty-five percent (25%) of the shares covered by the option on the first year anniversary of your employment commencement date and the remaining seventy-five percent
(75%) of the shares covered by the option will vest in thirty-six (36) equal monthly installments with the first monthly installment vesting one month following the first year anniversary of your
employment commencement date, as long as you remain in continuous service with the Company. 

  Page
 3
 
  

 Notwithstanding the foregoing, a portion of the shares subject to your outstanding option may vest on an
accelerated basis pursuant to Articles 8 or 9. Except as provided herein, such stock option will be subject to the provisions of the equity incentive plan of the Company under which the options are granted and the applicable form of stock option
agreement thereunder (the “Plan Documents”). 
 4. Other Activities During Employment. 

4.1 Activities. Except with the prior written consent of the CEO, you will not, during your employment with the Company,
undertake or engage in any other employment, occupation or business enterprise, other than ones in which you are a passive investor. Any consulting, whether ad hoc or other outside advisory work, must be discussed and agreed on with the CEO before
undertaking such work. The one exception to this is our agreement that you may continue in your Board of Directors role at Inversago while employed by CymaBay. Finally, you may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of your job duties for the Company. 

4.2 Investments and Interests. Except as permitted by the first sentence of Section 4.1 and by Section 4.3, during
your employment you agree not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by you to be adverse or antagonistic to the Company, or its business or prospects, financial or otherwise. 

4.3 Noncompetition. During the term of your employment by the Company, except on behalf of the Company, you will not directly or
indirectly, whether as an officer, director, stockholder, partner, proprietor, associate, representative, consultant, or in any capacity whatsoever engage in, become financially interested in, be employed by or have any business connection with any
other person, corporation, firm, partnership or other entity whatsoever that competes with the Company anywhere in the world, in any line of business engaged in (or planned to be engaged in) by the Company; provided, however, that anything
above to the contrary notwithstanding, you may own, as a passive investor, securities of any entity, so long as your direct holdings in any one such corporation do not in the aggregate constitute more than one percent (1%) of the voting stock of
such corporation. 
 5. Company Policies; Confidential Information and Inventions Agreement. As a condition of your
employment, you are required to execute the Company’s Employee Agreement on Confidential Information and Inventions, a copy of which is attached as Exhibit A. You further acknowledge your obligation to abide by the Company’s rules,
policies and procedures. 
 6. Immigration. The Immigration Reform and Control Act of 1986 requires that every person present
proof to the Company of their identity and eligibility and/or authorization to accept employment with the Company. In order to comply with this law, and before you can become a Company employee, you must provide appropriate documentation to prove
both your identity and legal eligibility to be employed at the Company. Please be sure to bring this documentation with you to your employee orientation. If you are working in the United States on a VISA, you will need to provide copies of this
documentation at your employee orientation. Failure to do so may result in over withholding of taxes. 

  Page
 4
 
  

 7. Your Representations and Warranties. 

7.1 No Breach of Contract. You represent and warrant that the execution and delivery of this letter agreement by you and the
performance of your obligations hereunder will not conflict with or breach any agreement, order or decree to which you are a party or by which you are bound. You warrant that you are subject to no employment agreement or restrictive covenant
preventing full performance of your duties under this letter agreement. 
 7.2 No Conflict of Interest. You warrant that you
are not, to the best of your knowledge and belief, involved in any situation that might create, or appear to create, a conflict of interest with your loyalty to or duties for the Company. 

7.3 Notification of Materials or Documents from Other Employers. You further warrant that you have not brought and will not
bring to the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are not generally available to the public, unless you have obtained express written authorization from the
former employer for their possession and use. 
 7.4 Notification of Other Post-Employment Obligations. You also understand
that, as part of your employment with the Company, you are not to breach any obligation of confidentiality that you have to former employers, and you agree to honor all such obligations to former employers during your employment with the Company.

 8. Termination of Employment. 

8.1 At-Will Employment Relationship. Your employment with the Company shall be at-will. Either you or the Company may terminate the employment relationship at any time, with or without Cause, and with or without advance notice. 

8.2 Termination for Cause. 

(a) Subject to the terms of this Article 8 and to the terms of Article 9, if the Company terminates your employment at any time for
Cause (as defined below), your salary shall cease on the date of termination and you shall not be entitled to severance pay, COBRA premium payments, pay in lieu of notice or any other such compensation other than payment of accrued salary and
vacation and such other benefits as expressly required by applicable law or the terms of applicable benefit plans. Subject to the terms of this Article 8 and to the terms of Article 9, the continued vesting of any equity awards held by you shall
cease on your employment termination date, and your right to exercise vested equity awards shall be governed by the Plan Documents. 

(b) Definition of Cause. For purposes of this letter agreement, “Cause” means the occurrence of any one or more of
the following: (i) your conviction of, or plea of no contest, with respect to any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) your participation in a fraud or act of dishonesty that results in material harm to
the Company; (iii) your intentional material violation of any contract or agreement between you and the Company, including but not limited to this letter agreement or your Employee Agreement on Confidential Information and Inventions, or your
violation of any statutory duty that you owe to the Company, but only if you do not correct any such violation within thirty (30) days after written notice thereof has been provided to you (if such notice is reasonably practicable); or
(iv) your gross negligence or willful neglect of your job duties, as determined by the Board in good faith, but only if you do not correct such violation within thirty (30) days after written notice thereof has been provided to you (if
such notice is reasonably practicable). 

  Page
 5
 
  

 8.3 Severance Benefits for Termination Without Cause or Resignation for Good
Reason. 
 (a) If the Company terminates your employment without Cause and other than as a result of your death or disability,
or if you resign your employment for Good Reason (defined below), and provided such termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h),
without regard to any alternative definition thereunder, a “Separation from Service”), you will be eligible to receive the severance benefits described in this Section 8.3. 

(b) You will be eligible to receive, subject to payroll deductions and required withholdings and net of any amounts earned by you
pursuant to any employment or consulting arrangements obtained by you following such termination (other than the activities described in the last sentence of Section 4.1), continuation for twelve (12) months of the greater of your base
salary: (i) in effect as of such termination date; or (ii) as set forth in Section 3.1. In addition, you will be eligible to receive your annual discretionary bonus amount at the higher of that (a) in effect as of such
termination date; or (b) as set forth in Section 3.3, in either case determined as if all performance targets have been satisfied, pro-rated for the number of months elapsed in the year in which your
employment terminates, but in no event will you receive a bonus pro-rated for less than nine (9) months. You agree to notify the Company promptly of any amount earned by you from other employment or a
consulting engagement while you are receiving severance payments under this letter agreement. 
 (c) If you timely elect and remain
eligible for continued coverage of your group health insurance under COBRA, the Company will pay your premiums for COBRA coverage for up to twelve (12) months following your Separation from Service, provided that such payments shall cease if
you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. On the
60th day following your Separation from Service, the Company will make the first payment under this clause equal to the aggregate amount of payments that the Company would have paid through such
date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for
coverage under another employer’s group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause
will cease. 
 (d) You will receive acceleration of vesting of all of your then-outstanding and then-unvested equity award grants as
of the date of termination as to the number of shares that would have vested in their vesting schedules as if you had been in service for an additional twelve (12) months as of your Separation from Service. 

(e) Your receipt of any severance benefits under this Section 8.3 is contingent upon your signing and making effective within
sixty (60) days after the termination date, 

  Page
 6
 
  

 
a full, general release of all claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit B on or after the
termination date. The base salary and bonus severance will be paid in substantially equal installments over the twelve (12) month period following your Separation in Service according to the Company’s payroll procedures; provided,
however, that no payments will be made to you prior to the 60th day following your Separation from Service. On the first payroll pay day following the 60th day after your Separation from Service, the Company will pay you the cash severance
amounts you would have received on or prior to such date in a lump sum in compliance with Code Section 409A and the effectiveness of the release, with the balance of the cash payments being made as originally scheduled. 

(f) Definition of Good Reason. For purposes of this letter agreement, “Good Reason” shall mean any one of the
following events that occurs without your consent: (i) the material reduction in your responsibilities, authorities or functions as an employee of the Company (but not merely a change in reporting relationships); (ii) a material reduction in
your level of compensation (including base salary, fringe benefits and target bonus under any corporate-performance based bonus or incentive programs); (iii) a material change of your place of employment that results in an increase to your round
trip commute of more than twenty (20) miles; or (iv) the Company’s material breach of this letter agreement. Notwithstanding the foregoing, you must provide written notice to the CEO of the Company within thirty (30) days after
the date on which such event first occurs, and allow the Company thirty (30) days thereafter (the “Cure Period”) during which the Company may attempt to rescind or correct the matter giving rise to Good Reason. If the Company does not
rescind or correct the conduct giving rise to Good Reason to your reasonable satisfaction by the expiration of the Cure Period, your employment will then terminate with Good Reason as of such thirtieth day. 

8.4 Voluntary or Mutual Termination. You may voluntarily terminate your employment with the Company at any time without Good
Reason. If you terminate without Good Reason or if your employment terminates as a result of your death or disability, your salary shall cease on the date of termination and you shall not be entitled to severance, pay in lieu of notice or any other
such compensation other than payment of accrued salary and vacation and such other benefits as expressly required in such event by applicable law or the terms of applicable benefit plans. The continued vesting of any compensatory equity awards held
by you shall cease on the termination date, and your right to exercise vested awards (or be issued shares under such vested awards) shall be governed by the terms of the Company’s applicable compensatory equity plans and the corresponding award
agreements. 
 8.5 Application of Section 409A. If the Company (or, if applicable, the successor entity
thereto) determines that the severance payments and benefits provided for in this letter agreement (the “Agreement Payments”) constitute “deferred compensation” under Section 409A of the Internal Revenue Code (together, with
any state law of similar effect, “Section 409A”) and you are a “specified employee” of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) (a “Specified Employee”),
then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Agreement Payments shall be delayed as follows: on the earliest to occur of (i) the date that is
six months and one day after the termination date or (ii) the date of your death (such earliest date, the “Delayed Initial Payment Date”), the Company (or the successor entity thereto, as applicable)

  Page
 7
 
  

 
shall (A) pay to you a lump sum amount equal to the sum of the Agreement Payments that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the
payment of the Agreement Payments had not been delayed pursuant to this Section 8.5 and (B) commence paying the balance of the Agreement Payments in accordance with the applicable payment schedules set forth in this letter agreement. For
the avoidance of doubt, it is intended that (1) each installment of the Agreement Payments provided in this letter agreement is a separate “payment” for purposes of Section 409A, (2) all Agreement Payments satisfy, to the
greatest extent possible, the exemptions from the application of Section 409A provided under of Treasury Regulation 1.409A-1(b)(4) and 1.409A-1(b)(9)(iii), and
(3) the Agreement Payments consisting of COBRA premiums also satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation
1.409A-1(b)(9)(v). 
 9. Change in Control. 

9.1 Definitions. 

(a) “Change in Control” shall mean an Ownership Change Event (as defined below) or a series of related Ownership Change
Events (collectively, a “Transaction”) wherein the stockholders of the Company immediately before the Transaction do not retain direct or indirect beneficial ownership of more than fifty percent (50%) of the total combined voting power of
the outstanding securities of the Company or, in the case of a Transaction described in Section 9.1(b)(iii), the corporation or other business entity to which the assets of the Company were transferred (the “Transferee”), as the case
may be. For purposes of the preceding sentence, indirect beneficial ownership shall include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities that own the
Company or the Transferee, as the case may be, either directly or through one or more subsidiary corporations or other business entities. 

(b) An “Ownership Change Event” shall be deemed to have occurred if any of the following occurs with respect to the Company:
(i) the direct or indirect sale or exchange in a single or series of related transactions by the stockholders of the Company of more than fifty percent (50%) of the voting stock of the Company; (ii) a merger or consolidation in which the
Company is a party; or (iii) the sale, exchange or transfer of all or substantially all of the assets of the Company. 
 9.2
Severance. On the consummation of any Change in Control any remaining unvested portion of your equity awards will be accelerated such that fifty percent (50%) of your outstanding and then-unvested equity awards become fully vested and
exercisable as of the date of the Change in Control (the “Acceleration”). If on or within twelve (12) months following a Change in Control, the Company or a successor corporation terminates your employment without Cause and other than
as a result of your death or disability, or you resign for Good Reason (a “Change in Control Termination”), and provided that such termination constitutes a Separation from Service, then subject to your obligations below, and in lieu of
any severance benefits set forth in Section 8.3 herein, you will be entitled to receive (collectively, the “Change in Control Severance Benefits”): 

(a) Subject to payroll deductions and required withholdings and net of any amounts earned by you pursuant to any employment or
consulting arrangements obtained by 

  Page
 8
 
  

 
you following such termination (other than the activities described in the last sentence of Section 4.1), continuation for twelve (12) months of the greater of your base salary:
(i) in effect as of such termination date; or (ii) as set forth in Section 3.1; or (iii) in effect on the date prior to the Change in Control. In addition, you will be eligible to receive one hundred and twenty-five percent
(125%) of your annual discretionary bonus amount at the higher of that (a) in effect as of such termination date; (b) as set forth in Section 3.3; or (c) in effect on the date prior to the Change in Control, in any case
determined as if all performance targets have been satisfied. 
 (b) You will receive acceleration of vesting of all of your
then-outstanding and then-unvested equity awards as of the date of termination such that the remaining fifty percent (50%) of your unvested equity awards following the Acceleration become fully vested and exercisable. 

(c) If you timely elect and remain eligible for continued coverage of your group health insurance under COBRA, the Company will pay
your premiums for COBRA coverage for up to fifteen (15) months following your Separation from Service, provided that such payments shall cease if you obtain full-time employment, or cease to be eligible for COBRA, within such period. You agree
to notify the Company promptly if you obtain full-time employment while the Company is paying your COBRA premiums under this letter agreement. On the 60th day following your Separation from
Service, the Company will make the first payment under this clause equal to the aggregate amount of payments that the Company would have paid through such date had such payments commenced on the Separation from Service through such 60th day, with the balance of the payments paid thereafter on the schedule described above. If you become eligible for coverage under another employer’s group health plan or otherwise cease to be
eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause will cease. 

(d) As a precondition of receiving the Change in Control Severance Benefits, you must first sign and make effective on or after the
termination date a full, general release of claims against the Company in a form acceptable to the Company containing the language set forth in the Release Agreement attached as Exhibit B. 

9.3 Parachute Payments. 

(a) If any payment or distribution in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to you or
for your benefit, whether under this letter agreement or otherwise (a “Payment”), would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”) (together with any
interest or penalties imposed with respect to such excise tax, the “Excise Tax”), then you will be entitled to receive from the Company an additional payment (the “Gross-Up Payment”) in an
amount equal to (i) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the Payment (the “First Reimbursement Payment”), (ii) all federal, state and local income taxes and employment taxes on
the First Reimbursement Payment, and (iii) all Excise Taxes (including any interest or penalties imposed with respect to such taxes) on the First Reimbursement Payment. 

(b) All determinations required to be made under this Section 9.3 including whether and when a
Gross-Up Payment is required and the amount of such Gross-Up 

  Page
 9
 
  

 
Payment and the assumptions to be utilized in arriving at such determination, shall be made by the nationally recognized certified public tax accounting firm used by the Company or, if such firm
declines to serve, such other nationally recognized certified public tax accounting firm as you may designate (the “Accounting Firm”). The Accounting Firm may make reasonable assumptions and approximations concerning applicable taxes and
may rely on reasonable, good-faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Accounting Firm shall provide its calculations, together with detailed supporting documentation, to the Company and you within
thirty (30) calendar days after the date on which your right to a Payment is triggered (if requested at that time by the Company or you) and/or at such other times as requested by the Company or you. If the Accounting Firm determines that no
Excise Tax is payable with respect to a Payment, it shall furnish the Company and you with an opinion reasonably acceptable to you that no Excise Tax will be imposed with respect to such Payment. If the Accounting Firm determines that an Excise Tax
is payable with respect to a Payment, it shall furnish to the Company and you an opinion reasonably acceptable to you of the amount of Excise Tax payable with respect to the Payments and the amount of Gross-Up
Payment due to you. The Company will pay the Gross-Up Payment to you within thirty (30) days of the date the Company receives the Accounting Firm’s opinion, but in no event later than the end of your
tax year following your tax year in which you pay the Excise Tax. The Company shall bear all reasonable expenses with respect to the determinations by the Accounting Firm required to be made hereunder. Any determination by the Accounting Firm shall
be binding upon the Company and you. 
 10. General Provisions. 

10.1 Dispute Resolution. To aid in the rapid and economical resolution of any disputes that may arise under this letter
agreement, the parties agree that any and all claims, disputes or controversies of any nature whatsoever arising from or regarding the interpretation, performance, negotiation, execution, enforcement or breach of this letter agreement, or your
relationship with the Company, including statutory claims, shall be resolved by confidential, final and binding arbitration conducted before a single arbitrator with Judicial Arbitration and Mediation Services, Inc. (“JAMS”) in San
Francisco, California, in accordance with JAMS’ then-applicable employment arbitration rules (which may be reviewed at www.jamsadr.com/rules-employment-arbitration/). The parties acknowledge that by agreeing to this arbitration
procedure, they waive the right to resolve any such dispute through a trial by jury, judge or administrative proceeding. The parties will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall:
(i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (ii) issue a written statement signed by the
arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based. The Company shall bear all
JAMS’ arbitration fees and administrative costs in excess of the amount of administrative fees (e.g., filing fees) that you would otherwise be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement shall
prevent any party from obtaining injunctive or other provisional relief in court to prevent irreparable harm pending the conclusion of any arbitration proceeding. 

10.2 Severability. Whenever possible, each provision of this letter agreement will be interpreted in such manner as to be
effective and valid under applicable law, but if any provision 

  Page
 10
 
  

 
of this letter agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will
not affect any other provision or any other jurisdiction, but such invalid, illegal or unenforceable provision will be reformed, construed and enforced in such jurisdiction so as to render it valid, legal, and enforceable consistent with the intent
of the parties insofar as possible. 
 10.3 Notices. Any notices provided hereunder must be in writing and shall be deemed
effective upon the earlier of personal delivery (including personal delivery by fax) or the next day after sending by overnight courier, to the Company at its primary office location and to you at your address as listed on the Company payroll. 

10.4 Waiver. If either party should waive any breach of any provisions of this letter agreement, you or the Company shall not
thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this letter agreement. 

10.5 Entire Agreement. This letter agreement, together with its exhibits, constitutes the entire and exclusive agreement between
you and the Company, and it supersedes any prior agreement, promise, representation, or statement, written or otherwise, between you and the Company with regard to this subject matter. It is entered into without reliance on any promise,
representation, statement or agreement other than those expressly contained or incorporated herein, and it cannot be modified or amended except in a writing signed by you and a duly authorized officer of the Company. 

10.6 Counterparts. This letter agreement may be executed in separate counterparts, any one of which need not contain signatures
of more than one party, but all of which taken together will constitute one and the same agreement. Copies of original signature pages sent by facsimile and/or PDF shall have the same effect as signature pages containing original signatures. 

10.7 Headings. The headings of the articles and sections hereof are inserted for convenience only and shall not be deemed to
constitute a part hereof nor to affect the meaning thereof. 
 10.8 Successors and Assigns. This letter agreement is intended
to bind and inure to the benefit of and be enforceable by you, the Company and your and its respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties hereunder and you may not assign any
of your rights hereunder without the written consent of the Company. 
 10.9 Governing Law. All questions concerning the
construction, validity and interpretation of this letter agreement will be governed by the law of the State of California as applied to contracts made and to be performed entirely within California. 

10.10 Attorneys’ Fees. If either party hereto brings any action to enforce your or its rights hereunder, the prevailing
party in such action shall be entitled to be paid by the other party such prevailing party’s reasonable attorneys’ fees and costs incurred in such action. 

Enclosed is your Employee Agreement on Confidential Information and Inventions, which you should read carefully. 

  Page
 11
 
  

 To indicate your acceptance of the Company’s offer, please sign this letter agreement in the space
provided below and return it to me along with the signed Exhibit A. This offer shall expire on May 10, 2021 if not accepted prior to such date. If you have any questions regarding this letter agreement, feel free to contact me. 

Sincerely, 
  

			
	CYMABAY THERAPEUTICS, INC.
		
	By:	 	 /s/ Sujal Shah

		
		 	Sujal Shah
		 	President and Chief Executive Officer
	
	Accepted and agreed:
	
	 /s/ Dennis Kim

	
	Dennis D. Kim, MD

 Employment Commencement Date: May 17, 2021 

EXHIBIT A – Employee Agreement on Confidential Information and Inventions 

EXHIBIT B – Release Agreement 

 EXHIBIT A 

EMPLOYEE AGREEMENT ON CONFIDENTIAL 

INFORMATION AND INVENTIONS 
 THIS AGREEMENT
is between CymaBay Therapeutics, Inc. a Delaware Corporation (“the Company”), and Dennis D. Kim, (the “Employee”). 

PURPOSE OF AGREEMENT 
 I want to
be employed by the Company, and the Company wants to employ me, provided that, in so doing, it can protect its trade secrets and inventions, ideas, information, business, and good will. 

In consideration of this purpose, and the mutual promises in this Agreement, I agree with the Company as follows: 

1. Term 
 (A) My
employment with the Company is an at-will relationship that may be terminated by either the Company or me with or without cause for any reason whatsoever at any time upon notice to the other party. 

(b) If my employment is terminated for any reason, I will be entitled only to the compensation earned by me as of the date of termination.

 2. Confidential Information. I will hold in confidence and use only for the benefit of the Company during the term of my
employment and for five years after the termination of my employment all Confidential Information of the Company, its Affiliates, and all Confidential Information of companies or persons other than the Company given to the Company under an agreement
prohibiting its disclosure. “Confidential Information” refers to valuable technical or business information that is not known by the public. By way of example, Confidential Information may include information relating to: inventions or
products, including unannounced products; research and development activities; requirements and specifications of specific customers and potential customers; nonpublic financial information; and quotations or proposals given to customers. 

These restrictions on disclosure do not apply if the information is or becomes publicly known through no wrongful act on my part or the
information is explicitly approved for release under such circumstances by an officer of the Company. 
 3. Disclosure and Assignment of
Inventions. I hereby assign to the Company my entire right, title and interest in all inventions. “Inventions” refer to (a) all technical or business innovations, whether or not patentable or copyrightable, made by me during the
term of my employment; and (b) all technical or business innovations, whether or not patentable, based upon the Company’s Confidential Information and made by me after leaving the Company’s employ. I will keep adequate written records
of all inventions made by me, such as notebooks, sketches, 

 
program listings and the like, which are the property of the Company. Notwithstanding the foregoing, I am not required to assign to the Company, although I must disclose, any inventions:
(a) for which no equipment, supplies, facilities or Confidential Information of the Company were used and which was developed entirely on my own time; (b) which at the time of conception or reduction to practice did not relate directly to
the business of the Company or the Company’s actual or demonstrably anticipated research or development and (c) which did not result from any work I performed for the Company. The disclosure of such inventions must be made so that the
parties can make a determination whether such inventions do in fact qualify for exclusion from assignment to the Company. The Company will keep confidential any such information I disclose. I will take all steps necessary to assist the Company in
securing any patents, copyrights or other protection for inventions which I am required to assign to the Company as provided above. If I am unable or unwilling, whether during my employment or after termination, to sign any papers needed to apply
for or pursue any patent or copyright registrations for inventions, I agree that the Company is my attorney-in-fact for that purpose and can sign such papers as my agent
and take any other actions necessary to pursue these registrations. 
 4. List of Inventions I Own. I have attached as Exhibit A a
list of inventions I own, which is a complete list of all technical or business innovations I own either alone or jointly with others on the date of this Agreement. I agree that I will not incorporate any of these prior inventions into products
being developed for the Company without the prior knowledge and written consent of the Company. Should the Company wish to use any of my inventions in its business, the Company will negotiate with me for a purchase of or license to use such
invention on mutually agreeable terms. If no such list is attached, or if no such inventions are listed thereon, I represent that I do not own any inventions at the time of signing this Agreement. 

5. Tangible Materials. All tangible materials that incorporate Confidential Information are the Company’s property, and I will
give all of these materials and any other documents and materials which are the property of the Company, including but not limited to all notes of any research or other work which I have performed for the Company and all biological materials
created, used or held by me in the course of my work for the Company, back to the Company at the termination of my employment or earlier upon the Company’s request. 

6. Solicitation of Employees. I understand that information about the Company’s employees, such as their skills, performance
ratings, and salary histories, constitutes Confidential Information owned by the Company. I agree that, for a period of twelve (12) months after termination of my employment for any reason, I will not, either directly or indirectly, solicit,
induce, recruit or encourage any of the Company’s employees to leave their employment, or take away such employees, or attempt to do any of these things, whether on my own behalf or on behalf of any other person, since to do so would
necessarily involve using Confidential Information. 
 8. Termination. In the event of termination of my employment for any reason, I
agree that, as requested by the Company, I will sign and deliver a “Termination Certification” in the form attached to this Agreement as Exhibit B. I also agree that the Company may give notice to my new employer of my duties under this
Agreement. 

 9. Duty of Loyalty. During my employment with the Company, I will not engage in any
business activity (either for my own profit or for anyone else) that competes with the Company’s business. 
 10. Duties to Third
Parties. I represent that, to the best of my knowledge, compliance with the terms of this Agreement will not violate any duty that I may have to anyone other than the Company (such as a former employer) to keep such person’s proprietary
information in confidence or to refrain from using that person’s patents or copyrights. If at any time during my employment with the Company, I am asked by the Company to perform work which I believe may cause me to violate a duty I have to
someone other than the Company, I will immediately inform an officer of the Company so that an assessment of the situation may be made. I also agree that I will not, during my employment with the Company, bring onto the Company’s premises, use
or disclose to the Company any proprietary information or trade secrets of any former employer or any other person without that person’s consent. 

11. Miscellaneous. This is the only agreement between the Company and myself about confidential information and the ownership of
inventions, and may not be modified, amended or terminated, in whole or in part, except in a writing signed by me and by an officer of the Company. Any later change in my title, compensation or duties will not affect this Agreement. This Agreement
will survive termination of my employment for any reason, and will continue for the benefit of and will be binding upon the successors, assigns, heirs and legal representatives of the Company and myself. Any waiver by the Company of a breach of any
of the obligations of this Agreement by me will not operate or be construed as a waiver of any other or subsequent breach by me. In the event any provision of this Agreement is held to be invalid, void or unenforceable, the remaining provisions will
nevertheless continue in full force and effect without being impaired or invalidated in any way. The prevailing party in any legal action brought by one party against the other and arising out of this Agreement shall be entitled, in addition to any
other rights and remedies it may have, to reimburse for its expenses, including court costs and reasonable attorney’s fees. This Agreement will be governed by the laws of the State of California governing contracts between residents to be
performed in the State of California. 
  

									
		 	CymaBay Therapeutics, Inc.	 		 		 	Employee
					
	By:	 	  
	 		 	By:	 	  

					
		 	Sujal Shah	 		 		 	Signature
		 	President and Chief Executive Officer	 		 		 	Dennis D. Kim, MD
			
	  
	 		 	  

		 	Date	 		 		 	Date

 EXHIBIT A 

List of Inventions I Own (see para. 4.) 

 EXHIBIT B 

Termination Certificate 

This is to certify that I do not have in my possession, nor have I failed to return, any devices, records, data, notes, reports, proposals,
lists, equipment, computer programs or listings, other documents or property or any reproductions of any of these materials belonging to CymaBay Therapeutics, Inc., a Delaware corporation, its subsidiaries, successors or assigns (collectively, the
“Company”). 
 I further certify that I have complied with all the terms of the Company’s Employee Confidential Information
and Inventions Agreement signed by me, including the reporting of any inventions and original works of authorship (as defined in that agreement) conceived or made buy me (solely or jointly with others) covered by that agreement. 

I further agree that, in compliance with the Employee Confidential Information and Inventions Agreement, I will preserve as confidential all
trade secrets, confidential knowledge, data or other proprietary information relating to inventions or products, including but not limited to unannounced products, research and development activities, requirements and specifications of specific
customers and potential customers, nonpublic financial information, and quotations or proposals given to customers, including any information disclosed to the Company in confidence by any third party. 

I further agree that for twelve (12) months from this date, I will not solicit, induce, recruit or encourage any of the Company’s
employees to leave their employment. 
  

	
	/template – do not sign/
	  

	Signature
	
	  

	Printed Name
	
	  

	Date

 EXHIBIT B 

RELEASE AGREEMENT 

(To be signed on or after the Separation Date) 

I understand that my employment with CymaBay Therapeutics, Inc. (the “Company”) terminated effective
                ,      (the “Separation Date”). The Company has agreed that if I choose to sign this Release Agreement
(“Release”), the Company will provide certain severance benefits (minus the required withholdings and deductions) pursuant to the terms of the employment agreement dated
                     (as amended, the “Letter Agreement”). I understand that I am not entitled to such severance benefits unless I sign
this Release, and it becomes fully effective. 
 I understand that this Release, together with the Letter Agreement, constitutes the
complete, final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated therein. 

I hereby confirm my obligations under my Employee Agreement on Confidential Information and Inventions with the Company. 

I hereby represent that I have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and
protections for which I am eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which I have not already
filed a claim. 
 In exchange for the consideration provided to me by this Release that I am not otherwise entitled to receive, I hereby
generally and completely release Company and its current and former directors, officers, employees, stockholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and
all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Release. This general release includes, but is not limited to:
(a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions,
vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership interests in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good
faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for
discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of
1967 (as amended) (“ADEA”), and the California Fair Employment and Housing Act (as amended). 

 Nothing in this Release shall prevent me from filing, cooperating with, or participating in
any proceeding before the Equal Employment Opportunity Commission, the Department of Labor, or the California Department of Fair Employment and Housing, except that I hereby acknowledge and agree that I shall not recover any monetary benefits in
connection with any such proceeding. 
 I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under
the ADEA (“ADEA Waiver”). I also acknowledge that the consideration given for the ADEA Waiver is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised by this
writing, as required by the ADEA, that: (a) my ADEA Waiver does not apply to any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release; (c) I have twenty-one (21) days to consider this Release (although I may choose to voluntarily sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke the ADEA Waiver; and
(e) the ADEA Waiver will not be effective until the date upon which the revocation period has expired unexercised, which will be the eighth day after I sign this Release. 

I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general
release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the
debtor.” I hereby expressly waive and relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims hereunder. 

I acknowledge that to become effective, I must sign and return this Release to the Company so that it is received not later than twenty-one (21) days following the date it is provided to me. 
 I accept and agree to the terms and conditions
stated above: 
  

							
		 		 	 /template – do not sign/

			
	  
	 		 	  

	Date	 		 	 Dennis D. KimExhibit
4.1

 

	NUMBER	 	UNITS
	U-__________

     
	 	 
	SEE
    REVERSE FOR CERTAIN DEFINITIONS	UNSDG
    ACQUISITION CORP.	 

 

CUSIP
90312P 207 

 

UNITS
CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE-HALF OF ONE REDEEMABLE WARRANT

 

THIS
CERTIFIES THAT _____________________________________________________________

 

is
the owner of _______________________________________________________________________ Units.

 

Each
Unit (“Unit”) consists of one (1) share of Class A common stock, with a par value of $0.0001 per share (“Common Stock”),
of UNSDG Acquisition Corp., a Delaware corporation (the “Company”) and one-half (1/2) of one redeemable warrant (“Warrant”).
Each whole redeemable Warrant entitles the holder thereof to purchase one (1) share of Common Stock at a price of $11.50 per full share
(subject to adjustment), upon the later to occur of (i) thirty (30) days after the Company’s completion of a merger, share exchange,
asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses
or entities (a “Business Combination”) or (ii) eighteen (18) months from the closing of the Company’s initial public
offering, and, unless exercised earlier, will expire at 5:00 p.m., New York City Time, on the date that is five (5) years after the date
on which the Company completes its initial Business Combination, or earlier upon redemption thereof or the Company’s liquidation.
The Common Stock and Warrants comprising the Units represented by this certificate are not transferable separately prior to the fifty-second
(52nd) day after the date of the prospectus relating to the Company’s initial public offering, unless EF Hutton,
division of Benchmark Capital Markets LLC determines that an earlier date is acceptable, but in no event
will the Common Stock and Warrants be traded separately until the Company files with the Securities and Exchange Commission (the “SEC”)
a current report on Form 8-K which includes an audited balance sheet reflecting the receipt by the Company of the gross proceeds from
its initial public offering including the proceeds received by the Company from the exercise of the over-allotment option thereto, if
the over-allotment option is exercised. If the over-allotment option is exercised after the date of the prospectus, we will file an amendment
to the Form 8-K or a new Form 8-K to provide updated financial information to reflect the exercise of the over-allotment option. We will
also include in the Form 8-K, or amendment thereto, or in a subsequent Form 8-K, information indicating if the underwriters has allowed
separate trading of the Common Stock and Warrant prior to the fifty-second (52nd) day after the date of the prospectus.

 

The
terms of the Warrants are governed by a warrant agreement (the “Warrant Agreement”), dated as of [●], 2021, between
the Company and Continental Stock Transfer & Trust Company, as the warrant agent, and are subject to the terms and provisions contained
therein, all of which terms and provisions the holder of this certificate consents to by acceptance hereof. Copies of the Warrant Agreement
are on file at the office of Continental Stock Transfer & Trust Company [1 State Street, 30th Floor, New York, New York 10004], and
are available to any Warrant Holder, on written request and without cost.

 

This
certificate is not valid unless countersigned by the Transfer Agent and Registrar of the Company.

 

Witness
the facsimile seal of the Company and the facsimile signatures of its duly authorized officers.

 

This
Unit Certificate shall be governed and construed in accordance with the internal laws of the State of New York, without regard to conflicts
of laws principles thereof.

 

	 	 	          [Seal]

    

	 	 	 
	By	 	 
	 	 	 
	Chairman
    	 	Chief
    Financial Officer

 

    	 

     

    

 

UNSDG
ACQUISITION CORP.

 

The
Company will furnish without charge to each shareholder who so requests, a statement of the powers, designations, preferences and relative,
participating, optional or other special rights of each class of shares or series thereof of the Company and the qualifications, limitations,
or restrictions of such preferences and/or rights.

 

The
following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written
out in full according to applicable laws or regulations:

 

	 	TEN
    COM –	as
    tenants in common	UNIF
    GIFT MIN ACT - 	_______
    	Custodian	_______
	 	TEN
    ENT – 	as
    tenants by the entireties	 	(Cust) 		(Minor)
	 	JT
    TEN – 	as
    joint tenants with right of survivorship	                                       under Uniform Gifts to Minors
	 	 	and
    not as tenants in common	                                       Act _____________ 
	 	 	 	 	(State)
              	

 

Additional
Abbreviations may also be used though not in the above list.

 

For
value received, ___________________________ hereby sell(s), assign(s) and transfer(s) unto

 

PLEASE
INSERT SOCIAL SECURITY OR OTHER

      IDENTIFYING
NUMBER OF ASSIGNEE(S)

 

	 

                                                                                 
	

 

________________________________________________________________________________________________

(PLEASE
PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE(S))

 

________________________________________________________________________________________________

 

________________________________________________________________________________________________

 

________________________________________________________________________________________
Units

 

represented
by the within Certificate, and do hereby irrevocably constitute and appoint

 

_____________________________________________________________________________________Attorney
to transfer the said Units on the books of the within named Company will full power of substitution in the premises.

 

Dated
__________________________

 

	 	
	 	Notice:	The
    signature to this assignment must correspond with the name as written upon the face of the certificate in every particular, without
    alteration or enlargement or any change whatever.

 

Signature(s)
Guaranteed:

 

__________________________________________________________________

			

THE
SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION

(BANKS,
STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH

MEMBERSHIP
IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM,

PURSUANT
TO S.E.C. RULE 17Ad-15).

 

In
each case, as more fully described in the Company’s final prospectus dated [•], 2021, the holder(s) of this certificate shall
be entitled to receive a pro-rata portion of certain funds held in the trust account established in connection with the Company’s
initial public offering only in the event that (i) the Company redeems the shares of Common Stock sold in the Company’s initial
public offering and liquidates because it does not consummate an initial business combination by [•], 2023 (or such later date as
the Company’s amended and restated certificate of incorporation may be amended to provide for), (ii) the Company offers to redeem
the shares of Common Stock sold in its initial public offering in connection with a stockholder vote to amend the Company’s amended
and restated certificate of incorporation (A) to modify the substance or timing of the ability of holders of Common Stock sold in the
Company’s initial public offering to seek redemption in connection with the Company’s initial business combination or the
Company’s obligation to redeem 100% of such Common Stock if it does not consummate an initial business combination by [•],
2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity,
and the holder(s) of this certificate elects to have the shares of Common Stock held by him, her or it redeemed pursuant to that offer,
or (iii) if the holder(s) seek(s) to redeem for cash his, her or its respective shares of Class A common stock in connection with a tender
offer (or proxy solicitation, solely in the event the Company seeks stockholder approval of the proposed initial business combination)
setting forth the details of a proposed initial business combination. In no other circumstances shall the holder(s) have any right or
interest of any kind in or to the trust account.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]